L'un des principaux objectifs de Life4me + - est de prévenir de nouveaux cas de VIH et d'autres IST, d'hépatite C et de tuberculose.

L'application aide à établir une communication anonyme entre les médecins et les personnes séropositives. Elle vous permet d'organiser facilement votre horaire de prise de médicaments et de définir des rappels cachés et personnalisés.

Toutes les actualités

Archive

✕

27 mars 2019, 15:52

641

FDA Completes Two ART Guidelines

FDA Completes Two ART Guidelines

The United States Food and Drug Administration (FDA) last Tuesday, March 19, announced the completion of two regulations designed to describe guidelines for developing antiretroviral drugs for children and systemic drugs for the prevention of HIV infection (PrEP).

25 mars 2019, 11:18

707

CDC: 40 percent of PLWH transmit HIV in the US

CDC: 40 percent of PLWH transmit HIV in the US

The U.S. Department of Health and Human Services (HHS) outlined a strategy to reduce by at least 90% the number of new HIV infections in the country by 2030. At the meeting, the results of a new report by the US Centers for Disease Control and Prevention (CDC) were announced, ...

22 mars 2019, 10:58

687

Healthcare providers should talk about “U = U” to all PLWH

Healthcare providers should talk about “U = U” to all PLWH

Employees of medical organizations should inform all patients with HIV that if the viral load in their body is reduced to an undetectable level, there is no risk of sexually transmitted infection. This was stated by a group of authors in response to the widespread practice ...

20 mars 2019, 10:01

690

DolPHIN-2: three quarters of HIV-positive women taking DTG from the third trimester gave birth to a healthy baby

DolPHIN-2: three quarters of HIV-positive women taking DTG from the third trimester gave birth to a healthy baby

At the international conference on retroviruses and opportunistic infections (CROI2019), the positive results of the research project DolPHIN-2, aimed at reducing the transmission of HIV from mother to child, were presented.

19 mars 2019, 12:49

674

Descovy is not inferior to Truvada as a daily PrEP

Descovy is not inferior to Truvada as a daily PrEP

Descovy's daily supplement, which contains a newer version of tenofovir combined with emtricitabine, has a comparable protective effect with the traditional pre-exposure prophylaxis of HIV infection, including tenofovir and emtricitabine (Truvada), said Dr. Brad Hear of ...

17 mars 2019, 09:45

602

TAF as PrEP: is efficiency a matter of form?

TAF as PrEP: is efficiency a matter of form?

Two studies of experimental pre-exposure prophylaxis schemes for HIV infection (PrEP) using the drug tenofovir alafenamide (TAF) immediately confirmed the effectiveness of therapy, but yielded conflicting results. According to experts who presented data at the Conference ...

16 mars 2019, 10:26

1413

On CROI were presented the latest data of the effectiveness and safety of fostemsavir

On CROI were presented the latest data of the effectiveness and safety of fostemsavir

On CROI were presented the latest information on studies of fostemsavir, a drug for the treatment of HIV infection of a fundamentally new type. Fostemsavir (FTR) is the first in its class prodrug of the Temsavir attachment inhibitor (TMR). TMR binds to HIV-1 by blocking ...

15 mars 2019, 08:41

1387

One in six South Africans has potential viral resistance to ART

One in six South Africans has potential viral resistance to ART

At the Conference on Retroviruses and Opportunistic Infections (CROI2019), was announced that up to 17% of South African people who had not previously been treated and who had evaded testing for HIV could have a drug-resistant strain of the virus, and more than half of those ...

14 mars 2019, 08:37

1442

MK-8591 implant has been shown to be highly effective at low dosages

MK-8591 implant has been shown to be highly effective at low dosages

#Merck's nucleoside reverse transcriptase translocation inhibitor (NRTTI) MK-8591 (outside the US and Canada - MSD) showed high antiviral activity against HIV-1 with a single dose of 0.5 mg, follows from preliminary results of clinical phase II trials (NCT03272347) presented ...

13 mars 2019, 08:19

1280

Second Generation HIV Maturation Inhibitor Presented in USA

Second Generation HIV Maturation Inhibitor Presented in USA

Dr. Edwin De Jesus of the Orlandian Center for Immunology (USA) last week presented the results of a phase IIa clinical trial of an innovative second-generation HIV maturation inhibitor GSK2838232. The drug, which previously demonstrated a clearly defined preclinical virological ...

1 2 3...91